ANCN Anchiano Therapeutics ADS

Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders

Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders

CAMBRIDGE, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) announced today that its board of directors approved the record date for the Company’s 2020 Annual General Meeting of Shareholders (the “Annual Meeting”) to be held on or about March 23, 2020.  The matters raised by Access Industries Holdings LLC and Clal Biotechnology Industries Ltd. will be addressed at the Annual Meeting.  Holders of the Company’s ordinary shares and holders of the Company’s American Depositary Shares at the close of business on February 17, 2020, the record date, will be entitled to receive notice of, and to vote at, the Annual Meeting.

About the Company

The Company is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer in areas of significant clinical need, with offices in Cambridge, MA and Jerusalem, Israel.  The Company is developing small-molecule pan-RAS inhibitors and inhibitors of PDE10 and the b-catenin pathway.  For more information on the Company, please visit

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to risks and uncertainties.  These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions, many of which are beyond the control of the Company, including, without limitation, the risk factors and other matters set forth in its filings with the Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2018.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Company Contact:

Frank Haluska, M.D., Ph.D.

President and Chief Executive Officer

Investor Contact:

Ashley R. Robinson

Managing Director

LifeSci Advisors, LLC

617-535-7742

EN
17/01/2020

Underlying

ANCNAnchiano Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anchiano Therapeutics ADS

 PRESS RELEASE
Free
ANCN Anchiano Therap...

Anchiano Announces Shareholder Approval of the Merger with Chemomab an...

Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $45.5 million, which will be used to advance the Chemomab pipeline TEL-AVIV, Israel, March 15, 2021 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (“Anchiano”; Nasdaq: ANCN) and (“Chemomab”), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseas...

March 15, 2021 1 EN
 PRESS RELEASE
Free
ANCN Anchiano Therap...

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merg...

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel CAMBRIDGE, Mass. and TEL-AVIV, Israel, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (“Anchiano”) (Nasdaq: ANCN), a...

December 15, 2020 1 EN
 PRESS RELEASE
Free
ANCN Anchiano Therap...

Anchiano Appoints Stan Polovets as Chairman of the Board

Anchiano Appoints Stan Polovets as Chairman of the Board CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced that Mr. Stan Polovets has been elected chairman of its board of directors. Mr. Polovets joined the board of Anchiano in April 2020. He previously served as CEO of AAR, a private equity firm with a global energy portfolio valued in excess of $25 billion, and represented TNK in its merger with BP to form one of the world’s largest oil companies and in the eventual sale of the merged company TNK-BP for $55 bill...

May 26, 2020 1 EN
 PRESS RELEASE
Free
ANCN Anchiano Therap...

Anchiano Therapeutics Reports First Quarter 2020 Financial Results

Anchiano Therapeutics Reports First Quarter 2020 Financial Results CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a preclinical biopharmaceutical company dedicated to the discovery and development of new cancer therapies designed to target the products of mutated genes that are drivers of human malignancies, today reported financial results for its first quarter ended March 31, 2020. “We have been very active this quarter and are continuing to transform as a company. We continue to focus on developing our targeted pan-mutant RAS...

May 11, 2020 1 EN
 PRESS RELEASE
Free
ANCN Anchiano Therap...

Anchiano Appoints Steve DiPalma as Chief Financial Officer

Anchiano Appoints Steve DiPalma as Chief Financial Officer CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr. DiPalma has served as a Senior Financial Advisor to Anchiano by agreement with Danforth Advisors since 2018; he will succeed Jonathan Burgin, who is leaving the Company as part of the planned closure of the Company’s Israel offices and facilities. Mr. Burgin will remain in the position of Chief Operating Officer until the final closure of...

May 5, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch